A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

ClinicalTrials.gov ID: NCT00904202

Public ClinicalTrials.gov record NCT00904202. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

Study identification

NCT ID: NCT00904202
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Enrollment: 62 participants

Conditions and interventions

Conditions

Interventions

Placebo Capsules + Placebo Patch Drug
Placebo capsules + Lidoderm® Drug
Gabapentin + Placebo Drug
Gabapentin + Lidoderm® Drug
Gabapentin 300 mg capsules 1800 mg/day + placebo patch Drug
Gabapentin 1800 mg/day + Lidoderm patch Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2002
Primary completion: May 31, 2003
Completion: Not listed
Last update posted: Jan 1, 2024

Started 2003

United States locations

U.S. sites: 7
U.S. states: 5
U.S. cities: 7

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	—	—
Not listed	Hueytown	Alabama	—	—
Not listed	Phoenix	Arizona	—	—
Not listed	Pembroke Pines	Florida	—	—
Not listed	New York	New York	—	—
Not listed	Rochester	New York	—	—
Not listed	Altoona	Pennsylvania	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00904202, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 1, 2024 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00904202 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →